News >

Clinical Trials Highlight Biomarker Progress in Lung Cancer

Gina Columbus @ginacolumbusonc
Published: Wednesday, Feb 21, 2018

Kartik Konduri, MD
Kartik Konduri, MD
Single-agent and combination immunotherapy continue to show positive results in patients with non–small cell lung cancer (NSCLC), especially those who have biomarker-driven disease.

For example, the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was reported to improve progression-free survival (PFS) versus chemotherapy in treatment-naïve patients with high tumor mutation burden (TMB), according to a news release of the phase III CheckMate-227 trial.

The same regimen also was found to demonstrate clinical activity in patients with small cell lung cancer (SCLC) who also have high TMB. In an exploratory analysis of the phase I/II CheckMate-032 study, nivolumab combined with ipilimumab induced an objective response rate (ORR) of 46% in these patients, who also had recurrent disease. In those who were treated with nivolumab alone, the ORR was 21%.

Kartik Konduri, MD, medical oncologist at Texas Oncology, co–medical director of the Chest Cancer Research and Treatment Center at Baylor Charles A. Sammons Cancer Center and chair of the chest site tumor committee at Baylor University Medical Center in Dallas, Texas, lectured on identified biomarkers in NSCLC during the 2018 OncLive® State of the Science Summit™ on Non–Small Cell Lung Cancer.

“The most important thing in lung cancer, at least in the nonsquamous NSCLC area, is that in many trials looking at different molecular mechanisms, one must consider evaluation upfront,” Konduri said. “Then, do not give up, and reevaluate with another biopsy if necessary, whether it be a blood test or tissue test or, in the circumstance that it may be possible for the patient, immunotherapy. Outcomes are certainly changing for patients who [respond to] immunotherapy-based treatment. They can be very long-lasting and, as we fine-tune that information and find the particular patient who fits this type of treatment, we will have an exciting time going forward.”

In an interview during the meeting, he shared insight on these molecular developments, recently presented or discussed clinical trials, and steps the field needs to take to continue moving in a biomarker-driven paradigm of NSCLC treatment.

OncLive: What is important to note in how the field is changing regarding biomarkers?

Konduri: The lung cancer landscape is changing and, as we go about on a day-to-day basis, we are finding new discoveries about how patients are potentially noted to have markers that can be utilized for treatment. Some of them can be molecular markers, where you are utilizing targeted therapies, and there are circumstances where secondary mutations of resistance mutations occur. Resistances can occur in the form of escape mechanisms or amplifications of the target, and new drugs have come out, which potentially can be evaluated for treatment.

Clinical trials going on in the space can be evaluated, as well. In terms of immunotherapy, we don’t have a perfect biomarker. We know that PD-L1 has a good response [as a biomarker], at least in a couple of trials, and it has been approved in the frontline setting for high expression with a particular drug.

We know that it is not a perfect biomarker, however, and we are in search of more. TMB and other evaluations, including T-effector gene signatures, are being looked at as possible biomarkers for the future. 

Can you expand on these clinical trials?

Multiple clinical trials are looking at immunotherapy biomarkers, and TMB has come to the forefront. Various trials have suggestive benefit—from evaluation in the CheckMate-026 trial, there was a TMB benefit in outcomes of PFS. There were also trials looking at small cell lung cancer, for example, such as in the CheckMate-032 trial. This was a small trial, but it did show benefit for high TMB having good response rates for patients with ipilimumab in combination with nivolumab or nivolumab on its own.

A recent trial that has been spoken about without actual data being presented is CheckMate-227, which is a combination of immunotherapy agents that have been shown to improve PFS for a specific subset of patients who are known to have high TMB. Then, there are trials that have looked at T-effector gene signatures, particularly the IMpower150 study, which has shown improvements in PFS. 

Of these trials, which would you consider to be the most practice changing?

The trial that has changed practice over the last few years was the KEYNOTE-024 trial. It allowed for high PD-L1 expression to suggest a subset of patients who will have a good benefit in terms of PFS and overall survival in lung cancer.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Year in Review™: Reflecting on Recent Evidence With an Eye to the Future of Lung Cancer ManagementMar 30, 20191.5
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication